Texas Biotech negotiating with Genentech to keep argatroban license; NDA deadline will not be met.
TEXAS BIOTECH RENEGOTIATING ARGATROBAN LICENSING WITH GENENTECH: the agreement as it now stands returns rights for Novastan (argatroban) to Genentech if Texas Biotechnology does not file an NDA by June 30 unless "there is good cause to delay such filing." The NDA will not be filed this year. The agreement, signed in May 1993, covers Canada and the U.S. Genentech licensed the antithrombolytic agent argatroban from Mitsubishi, which manufactures the drug for TBC.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth